Executive Vice President Clinical Programs
Dr. Segal has over 30 years of medical and biopharmaceutical / medical device experience including the design, conduct and execution of numerous multi-national, multi-site clinical programs and nonclinical studies. Dr. Segal previously served as Chief Medical Officer at Discovery Laboratories, Inc. (Nasdaq, now Windtree Therapeutics, Inc.), where, in addition to serving as executive management, he focused on many successful Federal funding opportunities, including important Biodefense initiatives. Dr. Segal has received well in excess of $10 million in NIH awards to evaluate novel drug and drug-device combination therapies. Previously, at Merck he held the position of Director, Cardiovascular Clinical Research where he was a key contributor to the approval and launch of Cozaar® (losartan). Prior to joining Merck, he was an Assistant Professor of Medicine in the Division of Nephrology / Transplantation at University of California, Los Angeles School of Medicine and served as an advisor to the Biotechnology Program at Northwestern University. Dr. Segal received his medical degree from the University of Pretoria Medical School, South Africa. Dr. Segal is a Diplomat of the American Board of Internal Medicine (with a sub-specialty certification in nephrology and transplantation) and is a Fellow of the American College of Physicians. He completed his internship and residency in Medicine at Sinai Hospital, Baltimore, and a clinical postdoctoral fellowship in General Medicine at The Johns Hopkins Hospital. He then completed a fellowship in Nephrology in the Division of Nephrology / Transplantation at the University of California, Los Angeles, as well as a research fellowship in Molecular Biology in the laboratory of the esteemed Arnold J. Berk, M.D., at the Molecular Biology Institute, UCLA.